Pranay Wal, Ankita Wal, Himangi Vig, Danish Mahmood, Mohd Masih Uzzaman Khan
Purpose: Both aging and neurodegenerative illnesses are thought to be influenced by mitochondrial malfunction and free radical formation. Deformities of the energy metabolism, mitochondrial genome polymorphisms, nuclear DNA genetic abnormalities associated with mitochondria, modifications of mitochondrial fusion or fission, variations in shape and size, variations in transit, modified mobility of mitochondria, transcription defects, and the emergence of misfolded proteins associated with mitochondria are all linked to Parkinson's disease. Method: This review is a condensed compilation of data from research that have been published between the years of 2014 and 2022, using search engines like Google Scholar, PubMed, and Scopus. Result: Mitochondrial transplantation is a one-of-a-kind treatment for mitochondrial diseases and deficits in mitochondrial biogenesis. The replacement of malfunctioning mitochondria with transplanted viable mitochondria using innovative methodologies has shown promising outcomes as a cure for Parkinson's, involving tissue sparing coupled with enhanced energy generation and lower oxidative damage. Numerous mitochondria-targeted therapies, including mitochondrial gene therapy, redox therapy, and others, have been investigated for their effectiveness and potency. Conclusion: The development of innovative therapeutics for mitochondria-directed treatments in Parkinson's disease may be aided by optimising mitochondrial dynamics. Many neurological diseases have been studied in animal and cellular models, and it has been found that mitochondrial maintenance can slow the death of neuronal cells. It has been hypothesised that drug therapies for neurodegenerative diseases that focus on mitochondrial dysfunction will help to delay the onset of neuronal dysfunction.
{"title":"Potential applications of mitochondrial therapy with a focus on Parkinson's disease and mitochondrial transplantation","authors":"Pranay Wal, Ankita Wal, Himangi Vig, Danish Mahmood, Mohd Masih Uzzaman Khan","doi":"10.34172/apb.2024.019","DOIUrl":"https://doi.org/10.34172/apb.2024.019","url":null,"abstract":"Purpose: Both aging and neurodegenerative illnesses are thought to be influenced by mitochondrial malfunction and free radical formation. Deformities of the energy metabolism, mitochondrial genome polymorphisms, nuclear DNA genetic abnormalities associated with mitochondria, modifications of mitochondrial fusion or fission, variations in shape and size, variations in transit, modified mobility of mitochondria, transcription defects, and the emergence of misfolded proteins associated with mitochondria are all linked to Parkinson's disease. Method: This review is a condensed compilation of data from research that have been published between the years of 2014 and 2022, using search engines like Google Scholar, PubMed, and Scopus. Result: Mitochondrial transplantation is a one-of-a-kind treatment for mitochondrial diseases and deficits in mitochondrial biogenesis. The replacement of malfunctioning mitochondria with transplanted viable mitochondria using innovative methodologies has shown promising outcomes as a cure for Parkinson's, involving tissue sparing coupled with enhanced energy generation and lower oxidative damage. Numerous mitochondria-targeted therapies, including mitochondrial gene therapy, redox therapy, and others, have been investigated for their effectiveness and potency. Conclusion: The development of innovative therapeutics for mitochondria-directed treatments in Parkinson's disease may be aided by optimising mitochondrial dynamics. Many neurological diseases have been studied in animal and cellular models, and it has been found that mitochondrial maintenance can slow the death of neuronal cells. It has been hypothesised that drug therapies for neurodegenerative diseases that focus on mitochondrial dysfunction will help to delay the onset of neuronal dysfunction.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135803767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hendris Wongso, Ahmad Kurniawan, Yanuar Setiadi, Crhisterra E. Kusumaningrum, Eva M. Widyasari, Teguh H.A. Wibawa, Isa Mahendra, Muhamad B. Febrian, Maula E. Sriyani, Iim Halimah, Isti Daruwati, Rudi Gunawan, Arifudin Achmad, Dwianto H. Nugraha, Ronny Lesmana, Ari S. Nugraha
Translocator protein 18-kDa, broadly known as TSPO, is a mitochondrial membrane protein, previously identified as the peripheral benzodiazepine receptor (PBR). TSPO involves in a broad number of biochemical events, such as steroidogenesis, mitochondrial cholesterol transport, cell survival and death, cell proliferation, and carcinogenesis. Several investigations have reported the roles of TSPO in various types of cancers, including colorectal cancer, brain cancer, melanoma, breast cancer, prostate cancer, and lung cancer. It was found that TSPO is upregulated in cancer cells, and it appears that its expression is parallel with an aggressive phenotype and/or poor prognosis. As a consequence, there is great potential for developing diagnostic and prognostic tools targeting the TSPO. In this regard, several radioligands targeting the TSPO have been identified, and some of the candidates have advanced to clinical trials. In recent years, image-guided surgery using hybrid probes bearing radioactive and fluorescence molecules has demonstrated promising outcomes in animal and human studies, and thus might serve as a valuable surgical navigator during cancer surgery. In general, current hybrid probes are built from various molecular platforms, including small molecules, nanoparticles, and antibodies. Although several TSPO-targeted imaging probes have been developed, their development for image-guided surgery of cancers is scarce. This review highlights recent findings of the involvement of TSPO in carcinogenesis, and provides a new perspective on the potential application of TSPO-targeted hybrid probes for image-guided surgery.
{"title":"Translocator Protein 18 kDa (TSPO): A Promising Molecular Target for Image-Guided Surgery of Solid Cancers","authors":"Hendris Wongso, Ahmad Kurniawan, Yanuar Setiadi, Crhisterra E. Kusumaningrum, Eva M. Widyasari, Teguh H.A. Wibawa, Isa Mahendra, Muhamad B. Febrian, Maula E. Sriyani, Iim Halimah, Isti Daruwati, Rudi Gunawan, Arifudin Achmad, Dwianto H. Nugraha, Ronny Lesmana, Ari S. Nugraha","doi":"10.34172/apb.2024.015","DOIUrl":"https://doi.org/10.34172/apb.2024.015","url":null,"abstract":"Translocator protein 18-kDa, broadly known as TSPO, is a mitochondrial membrane protein, previously identified as the peripheral benzodiazepine receptor (PBR). TSPO involves in a broad number of biochemical events, such as steroidogenesis, mitochondrial cholesterol transport, cell survival and death, cell proliferation, and carcinogenesis. Several investigations have reported the roles of TSPO in various types of cancers, including colorectal cancer, brain cancer, melanoma, breast cancer, prostate cancer, and lung cancer. It was found that TSPO is upregulated in cancer cells, and it appears that its expression is parallel with an aggressive phenotype and/or poor prognosis. As a consequence, there is great potential for developing diagnostic and prognostic tools targeting the TSPO. In this regard, several radioligands targeting the TSPO have been identified, and some of the candidates have advanced to clinical trials. In recent years, image-guided surgery using hybrid probes bearing radioactive and fluorescence molecules has demonstrated promising outcomes in animal and human studies, and thus might serve as a valuable surgical navigator during cancer surgery. In general, current hybrid probes are built from various molecular platforms, including small molecules, nanoparticles, and antibodies. Although several TSPO-targeted imaging probes have been developed, their development for image-guided surgery of cancers is scarce. This review highlights recent findings of the involvement of TSPO in carcinogenesis, and provides a new perspective on the potential application of TSPO-targeted hybrid probes for image-guided surgery.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135803837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mehdi Dadkhah, Marilyn H Oermann, Mihály Hegedüs, Raghu Raman, Lóránt Dénes Dávid
Purpose: Academic and other researchers have limited tools with which to address the current proliferation of predatory and hijacked journals. These journals can have negative effects on science, research funding, and the dissemination of information. As most predatory and hijacked journals are not error free, this study used ChatGPT, an artificial intelligence technology tool, to conduct an evaluation of journal quality. Methods: Predatory and hijacked journals were analyzed for reliability using ChatGPT, and the reliability of result have been discussed. Results: It shows that ChatGPT is an unreliable tool for journal quality evaluation for both hijacked and predatory journals. Conclusion: To show how address this gap, an early trial version of Journal Checker Chatbot has been developed and is discussed as an alternative chatbot that can assist researchers in detecting hijacked journals.
{"title":"Diagnosis Reliability of ChatGPT for Journal Evaluation","authors":"Mehdi Dadkhah, Marilyn H Oermann, Mihály Hegedüs, Raghu Raman, Lóránt Dénes Dávid","doi":"10.34172/apb.2024.020","DOIUrl":"https://doi.org/10.34172/apb.2024.020","url":null,"abstract":"Purpose: Academic and other researchers have limited tools with which to address the current proliferation of predatory and hijacked journals. These journals can have negative effects on science, research funding, and the dissemination of information. As most predatory and hijacked journals are not error free, this study used ChatGPT, an artificial intelligence technology tool, to conduct an evaluation of journal quality. Methods: Predatory and hijacked journals were analyzed for reliability using ChatGPT, and the reliability of result have been discussed. Results: It shows that ChatGPT is an unreliable tool for journal quality evaluation for both hijacked and predatory journals. Conclusion: To show how address this gap, an early trial version of Journal Checker Chatbot has been developed and is discussed as an alternative chatbot that can assist researchers in detecting hijacked journals.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135803760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Delivery and formulation of oral therapeutic peptide/protein-based biotechnological drugs have always been a challenge for the pharmaceutical industry. The bioavailability of oral biopharmaceuticals mainly relies on their gastrointestinal solubility and permeability which are affected by their poor membrane penetration, high molecular weight and proteolytic (chemical and enzymatic) degradation resulting in limited delivery and therapeutic efficacy. The present review article highlights the challenges and limitations of oral delivery of therapeutic peptide/protein-based drugs focusing on the application, potential and importance of solid lipid nanoparticles (SLNs) and nanostructure lipid carriers (NLCs) as lipid-based drug delivery systems (LBDDSs) and their advantages and drawbacks. LBDDSs, due to their lipid-based matrix can encapsulate both lipophilic and hydrophilic drugs, and by reducing the first-pass effect and avoiding proteolytic degradation offer improved drug stability, dissolution rate, absorption, bioavailability and controlled drug release. Furthermore, their small size, high surface area and surface modification increase their mucosal adhesion, tissue-targeted distribution, physiological function and half-life. Properties such as simple preparation, high-scale manufacturing, biodegradability, biocompatibility, prolonged half-life, lower toxicity, lower adverse effects, lipid-based structure, higher drug encapsulation rate and various drug release profile compared to other similar carrier systems makes LBDDSs a promising drug delivery system. Nevertheless, undesired physicochemical features of peptide/protein drug development and discovery such as plasma stability, membrane permeability and circulation half-life remain a serious challenge which should be addressed in future.
{"title":"Lipid-based nanoparticles as oral drug delivery systems: overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide/protein-based drugs","authors":"Soheil Mehrdadi","doi":"10.34172/apb.2024.016","DOIUrl":"https://doi.org/10.34172/apb.2024.016","url":null,"abstract":"Delivery and formulation of oral therapeutic peptide/protein-based biotechnological drugs have always been a challenge for the pharmaceutical industry. The bioavailability of oral biopharmaceuticals mainly relies on their gastrointestinal solubility and permeability which are affected by their poor membrane penetration, high molecular weight and proteolytic (chemical and enzymatic) degradation resulting in limited delivery and therapeutic efficacy. The present review article highlights the challenges and limitations of oral delivery of therapeutic peptide/protein-based drugs focusing on the application, potential and importance of solid lipid nanoparticles (SLNs) and nanostructure lipid carriers (NLCs) as lipid-based drug delivery systems (LBDDSs) and their advantages and drawbacks. LBDDSs, due to their lipid-based matrix can encapsulate both lipophilic and hydrophilic drugs, and by reducing the first-pass effect and avoiding proteolytic degradation offer improved drug stability, dissolution rate, absorption, bioavailability and controlled drug release. Furthermore, their small size, high surface area and surface modification increase their mucosal adhesion, tissue-targeted distribution, physiological function and half-life. Properties such as simple preparation, high-scale manufacturing, biodegradability, biocompatibility, prolonged half-life, lower toxicity, lower adverse effects, lipid-based structure, higher drug encapsulation rate and various drug release profile compared to other similar carrier systems makes LBDDSs a promising drug delivery system. Nevertheless, undesired physicochemical features of peptide/protein drug development and discovery such as plasma stability, membrane permeability and circulation half-life remain a serious challenge which should be addressed in future.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135804136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}